Chronic Lymphocytic Leukemia (CLL) patients with +12 have been reported to have specific clinical and biologic features. We performed an analysis of the association between demographic; clinical; laboratory; biologic features and outcome in CLL patients with +12 to identify parameters predictive of disease progression; time to treatment; and survival. The study included 487 treatment-naive CLL patients with +12 from 15 academic centers; diagnosed between January 2000 and July 2016; and 816 treatment-naïve patients with absence of Fluorescence In Situ Hybridization (FISH) abnormalities. A cohort of 250 patients with +12 CLL followed at a single US institution was used for external validation. In patients with +12; parameters associated with worse prognosis in the multivariate model were high Lactate DeHydrogenase (LDH) and β-2- microglobulin and unmutated immunoglobulin heavy-chain variable region gene (IGHV). CLL patients with +12 and high LDH levels showed a shorter Progression-Free-Survival (PFS) (30 months vs. 65 months; p < 0.001), Treatment-Free-Survival (TFS) (33 months vs. 69 months; p < 0.001), Overall Survival (OS) (131 months vs. 181 months; p < 0.001) and greater CLL-related mortality (29% vs. 11% at 10 years; p < 0.001) when compared with +12 CLL patients with normal LDH levels. The same differences were observed in the validation cohort. These data suggest that serum LDH levels can predict PFS; TFS; OS and CLL-specific survival in CLL patients with +12.

Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 / Autore, F.; Strati, P.; Innocenti, I.; Corrente, F.; Trentin, L.; Cortelezzi, A.; Visco, C.; Coscia, M.; Cuneo, A.; Gozzetti, A.; Mauro, F. R.; Frustaci, A. M.; Gentile, M.; Morabito, F.; Molica, S.; Falcucci, P.; D'Arena, G.; Murru, R.; Vincelli, D.; Efremov, D. G.; Ferretti, A.; Rigolin, G. M.; Vitale, C.; Tisi, M. C.; Reda, G.; Visentin, A.; Sica, S.; Foa, R.; Ferrajoli, A.; Laurenti, L.. - In: CANCERS. - ISSN 2072-6694. - 11:7(2019), p. 896. [10.3390/cancers11070896]

Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12

Mauro F. R.;Murru R.;Foa R.;Laurenti L.
2019

Abstract

Chronic Lymphocytic Leukemia (CLL) patients with +12 have been reported to have specific clinical and biologic features. We performed an analysis of the association between demographic; clinical; laboratory; biologic features and outcome in CLL patients with +12 to identify parameters predictive of disease progression; time to treatment; and survival. The study included 487 treatment-naive CLL patients with +12 from 15 academic centers; diagnosed between January 2000 and July 2016; and 816 treatment-naïve patients with absence of Fluorescence In Situ Hybridization (FISH) abnormalities. A cohort of 250 patients with +12 CLL followed at a single US institution was used for external validation. In patients with +12; parameters associated with worse prognosis in the multivariate model were high Lactate DeHydrogenase (LDH) and β-2- microglobulin and unmutated immunoglobulin heavy-chain variable region gene (IGHV). CLL patients with +12 and high LDH levels showed a shorter Progression-Free-Survival (PFS) (30 months vs. 65 months; p < 0.001), Treatment-Free-Survival (TFS) (33 months vs. 69 months; p < 0.001), Overall Survival (OS) (131 months vs. 181 months; p < 0.001) and greater CLL-related mortality (29% vs. 11% at 10 years; p < 0.001) when compared with +12 CLL patients with normal LDH levels. The same differences were observed in the validation cohort. These data suggest that serum LDH levels can predict PFS; TFS; OS and CLL-specific survival in CLL patients with +12.
2019
CLL; LDH; Prognosis; Trisomy 12
01 Pubblicazione su rivista::01a Articolo in rivista
Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12 / Autore, F.; Strati, P.; Innocenti, I.; Corrente, F.; Trentin, L.; Cortelezzi, A.; Visco, C.; Coscia, M.; Cuneo, A.; Gozzetti, A.; Mauro, F. R.; Frustaci, A. M.; Gentile, M.; Morabito, F.; Molica, S.; Falcucci, P.; D'Arena, G.; Murru, R.; Vincelli, D.; Efremov, D. G.; Ferretti, A.; Rigolin, G. M.; Vitale, C.; Tisi, M. C.; Reda, G.; Visentin, A.; Sica, S.; Foa, R.; Ferrajoli, A.; Laurenti, L.. - In: CANCERS. - ISSN 2072-6694. - 11:7(2019), p. 896. [10.3390/cancers11070896]
File allegati a questo prodotto
File Dimensione Formato  
Autore_elevate-lactate_2019.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.68 MB
Formato Adobe PDF
1.68 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1411205
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 11
social impact